Ludwig Enterprises (Ludwig Enterprises) Cash, Cash Equivalents, Marketable Securities : $0.35 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Cash, Cash Equivalents, Marketable Securities?

Ludwig Enterprises's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($0.01 Mil) to Dec. 2023 ($0.11 Mil) and increased from Dec. 2023 ($0.11 Mil) to Mar. 2024 ($0.35 Mil).

Ludwig Enterprises's annual cash, cash equivalents, marketable securities increased from . 20 ($0.00 Mil) to Dec. 2022 ($0.52 Mil) but then declined from Dec. 2022 ($0.52 Mil) to Dec. 2023 ($0.11 Mil).

Ludwig Enterprises Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Ludwig Enterprises's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Cash, Cash Equivalents, Marketable Securities Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

0.52

0.11

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			0.52	-	0.01	0.11	0.35

Ludwig Enterprises Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Ludwig Enterprises (OTCPK:LUDG) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Ludwig Enterprises Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ludwig Enterprises's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.